These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 27449546

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
    Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, Redden DT, Saag KG, Foster PJ, Chen L, Curtis JR.
    Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [Abstract] [Full Text] [Related]

  • 6. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [Abstract] [Full Text] [Related]

  • 7. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M, Cimmino MA, Perez-Ruiz F.
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [Abstract] [Full Text] [Related]

  • 8. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
    Timilsina S, Brittan K, O'Dell JR, Brophy M, Davis-Karim A, Henrie AM, Neogi T, Newcomb J, Palevsky PM, Pillinger MH, Pittman D, Taylor TH, Wu H, Mikuls TR.
    Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007
    [Abstract] [Full Text] [Related]

  • 9. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA, Akhras KS, Shiozawa A.
    Arthritis Res Ther; 2015 May 12; 17(1):120. PubMed ID: 25963969
    [Abstract] [Full Text] [Related]

  • 10. Serum urate levels and gout flares: analysis from managed care data.
    Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.
    J Clin Rheumatol; 2006 Apr 12; 12(2):61-5. PubMed ID: 16601538
    [Abstract] [Full Text] [Related]

  • 11. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC, Salido EO, Penserga EG.
    Mod Rheumatol; 2021 May 12; 31(3):755-761. PubMed ID: 32701037
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF, Santosa A, Low BPL, Tan PSH, Khong ZW, Lim AYN, Teng GG, Tay SH.
    Int J Rheum Dis; 2020 Aug 12; 23(9):1136-1144. PubMed ID: 32483906
    [Abstract] [Full Text] [Related]

  • 14. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP, Gilliland WR.
    Clin Pharmacol Ther; 2011 Sep 12; 90(3):363-4. PubMed ID: 21862966
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.
    Goldfien RD, Ng MS, Yip G, Hwe A, Jacobson A, Pressman A, Avins AL.
    BMJ Open; 2014 Jan 10; 4(1):e003627. PubMed ID: 24413343
    [Abstract] [Full Text] [Related]

  • 16. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.
    Arthritis Care Res (Hoboken); 2012 Feb 10; 64(2):256-61. PubMed ID: 22052584
    [Abstract] [Full Text] [Related]

  • 17. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B, Bennett K, Silke C, Whelan B.
    Clin Rheumatol; 2016 Mar 10; 35(3):715-21. PubMed ID: 25409858
    [Abstract] [Full Text] [Related]

  • 18. Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study).
    Stamp L, Te Karu L, Reid S, Wright DFB, Frampton C, Tuitaupe VS, Dalbeth N.
    BMJ Open; 2024 Aug 03; 14(8):e084665. PubMed ID: 39097306
    [Abstract] [Full Text] [Related]

  • 19. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
    Borghi C, Perez-Ruiz F.
    Eur Rev Med Pharmacol Sci; 2016 Mar 03; 20(5):983-92. PubMed ID: 27010159
    [Abstract] [Full Text] [Related]

  • 20. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Huang IJ, Liew JW, Morcos MB, Zuo S, Crawford C, Bays AM.
    Rheumatol Int; 2019 Sep 03; 39(9):1637-1641. PubMed ID: 31147732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.